Senate Special Committee on Aging Examines Drug Pricing

March 17, 2016
Contact: Ben Jenkins
Email: [email protected]

Senate Special Committee on Aging Examines Drug Pricing

Ahead of this morning's Senate Special Committee on Aging hearing on drug pricing, John Rother, executive director of the Campaign for Sustainable Rx Pricing issued the following statement:

"Today's hearing shows that fighting high prescription drug prices is truly a bipartisan battle. Companies are buying decades-old prescription drugs and jacking up prices on vulnerable patients. It's unconscionable. We need more transparency and competition in the prescription drug market to protect Americans from this appalling practice."

And, the problem of rising prescription drug prices is even more widespread than just Turing Pharmaceuticals or a few bad actors. Learn more about the startling pace of across-the-board price increases here in our fact sheet.

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.